Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Horizon Therapeutics (HZNP)

Horizon Therapeutics (HZNP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 16,198,852
  • Shares Outstanding, K 206,460
  • Annual Sales, $ 1,300 M
  • Annual Income, $ 573,020 K
  • 60-Month Beta 1.09
  • Price/Sales 12.65
  • Price/Cash Flow 22.95
  • Price/Book 6.43
Trade HZNP with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 0.96
  • Number of Estimates 6
  • High Estimate 1.13
  • Low Estimate 0.79
  • Prior Year 0.64
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
73.88 +1.52%
on 09/24/20
86.67 -13.46%
on 10/09/20
-4.93 (-6.17%)
since 09/18/20
3-Month
56.20 +33.45%
on 07/24/20
86.67 -13.46%
on 10/09/20
+16.19 (+27.53%)
since 07/20/20
52-Week
23.81 +214.99%
on 03/18/20
86.67 -13.46%
on 10/09/20
+47.60 (+173.72%)
since 10/18/19

Most Recent Stories

More News
Horizon Therapeutics plc Announces TEPEZZA(R) (teprotumumab-trbw) Selected as a Winner of the Chicago Innovation Award

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that TEPEZZA(R) (teprotumumab-trbw) has been selected as a winner of the 19th Annual Chicago Innovation Award. TEPEZZA is the first and only medicine...

HZNP : 74.96 (-4.46%)
FORTUNE and Great Place to Work(R) Name Horizon Therapeutics plc to Best Medium Workplaces List for Fifth Consecutive Year

Horizon Therapeutics plc (NASDAQ: HZNP) announced today that it has been selected to FORTUNE's Best Medium Workplaces 2020 list for the fifth consecutive year. Horizon ranked 10th out of 100 other medium-sized...

HZNP : 74.96 (-4.46%)
Is Horizon Therapeutics Public Limited (HZNP) Outperforming Other Medical Stocks This Year?

Is (HZNP) Outperforming Other Medical Stocks This Year?

HZNP : 74.96 (-4.46%)
Vertex to End Phase II Study on AAT Deficiency Candidate

Vertex (VRTX) to discontinue phase II study on VX-814 based on the liver enzyme elevations observed and the determination that it would be difficult to safely achieve targeted exposure levels.

VRTX : 214.99 (-2.50%)
EBS : 97.40 (+1.49%)
HZNP : 74.96 (-4.46%)
CRSP : 105.95 (-1.64%)
TEPEZZA(R) (teprotumumab-trbw) Data from the Phase 2 Clinical Trial Evaluate Longer-Term Responses in People Living with Thyroid Eye Disease (TED)

Horizon Therapeutics plc (Nasdaq: HZNP) today announced new long-term follow-up data from the Phase 2 clinical trial of TEPEZZA(R) (teprotumumab-trbw), which showed a sustained response up to one year...

HZNP : 74.96 (-4.46%)
Why the Earnings Surprise Streak Could Continue for Horizon Therapeutics (HZNP)

Horizon Therapeutics (HZNP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

HZNP : 74.96 (-4.46%)
New Data Evaluating KRYSTEXXA(R) (pegloticase injection) With Concomitant Immunomodulation to Be Presented at the American College of Rheumatology Convergence 2020

-- Oral presentation on Nov. 7 at 5:20 p.m. ET discussing data from RECIPE, the randomized controlled trial studying the concomitant use of KRYSTEXXA with the immunomodulator mycophenolate mofetil --

HZNP : 74.96 (-4.46%)
Horizon Therapeutics plc to Release Third-Quarter 2020 Financial Results and Host Webcast on Nov. 2, 2020

Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its third-quarter 2020 financial results will be released on Monday, Nov. 2, 2020. Following the announcement, Horizon's management will host...

HZNP : 74.96 (-4.46%)
Horizon Therapeutics plc Named One of San Francisco Bay Area's Best and Brightest Companies to Work For

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named one of "San Francisco Bay Area's Best and Brightest Companies to Work For." This is the first year that Horizon has been named...

HZNP : 74.96 (-4.46%)
Bristol Myers' Opdivo & Yervoy Win FDA Nod for Mesothelioma

Bristol Myers' (BMY) Opdivo in combination with Yervoy gets an FDA approval for malignant pleural mesothelioma.

RHHBY : 42.2699 (-0.21%)
MRK : 78.31 (-0.46%)
BMY : 60.89 (+0.20%)
HZNP : 74.96 (-4.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Horizon Therapeutics PLC is a biopharmaceutical company. It is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines which address unmet medical needs. The Company markets medicines through its orphan, rheumatology and primary care business units. ...

See More

Key Turning Points

2nd Resistance Point 81.63
1st Resistance Point 80.04
Last Price 74.96
1st Support Level 77.19
2nd Support Level 75.92

See More

52-Week High 86.67
Last Price 74.96
Fibonacci 61.8% 62.66
Fibonacci 50% 55.24
Fibonacci 38.2% 47.82
52-Week Low 23.81

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar